# US 2004/0062804 A1 · Modified release dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0062804 A1
- Document ID: US20040062804A1
- Status: Published application
- Kind: A1
- Application number: 10/432,488
- Filed: 2003-10-01
- Published: 2004-04-01
- Earliest claimed: 2001-09-28
- Inventors: Der-Yang Lee; Shun-Por Li; Daniel McTeigue; Narendra Parikh; Harry S. Sowden; Martin Thomas; David Wynn
- Web page: https://patentgrep.com/patent/US20040062804A1

## CPC

- A23G 3/04: Sugar-cookers
- A23G 1/54: Composite products, e.g. layered, {laminated,} coated or filled
- A23G 3/0029: {Moulding processes for hollow products, e.g. opened shell}
- A23G 3/368: {containing vitamins, antibiotics}
- A23G 3/54: Composite products, e.g. layered, coated, filled
- A23L 29/30: containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin (products from apiculture A23L21/20; artificial sweetening agents A23L27/30)
- A61J 3/005: {Coating of tablets or the like (coating of sweetmeats or confectionery A23G3/20; coating of granules in general B01J2/006)}
- A61J 3/06: into the form of pills, lozenges or dragees
- A61J 3/10: into the form of compressed tablets (tablet presses B30B11/00)
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/2095: {Tabletting processes}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2826: {Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 9/286: {Polysaccharides, e.g. gums; Cyclodextrin}
- A61K 9/2873: {Proteins, e.g. gelatin}
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B30B 11/08: co-operating with moulds carried by a turntable
- B30B 11/34: for coating articles, e.g. tablets
- B30B 15/302: {Feeding material in particulate or plastic state to moulding presses}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- Y10T 428/1352: Polymer or resin containing [i.e., natural or synthetic]
- A23G: COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B30B: PRESSES IN GENERAL (producing ultra-high pressure or ultra-high pressure and high temperature to effect modifications of a substance, e.g. for making artificial diamonds B01J3/00 ){(compressing means for refuse receptacles B65F1/1405)}
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A dosage form comprises: (a) at least one active ingredient; (b) a core; and(c) a shell which surrounds the core, wherein the shell is substantially free of pores having a diameter of 0.5-5.0 microns, and the shell comprises a first shell portion and a second shell portion which are compositionally different and the dosage form provides a modified release profile of the active ingredient upon contacting of the dosage form with a liquid medium. In another embodiment, the dosage form comprises: (a) at least one active ingredient; (b) a core comprising first and second core portions; and (c) a shell which surrounds the core, wherein the shell comprises first and second shell portions such that the first shell portion resides upon the first core portion and the second shell portion resides upon the second core portion, and at least one of the first or second shell portions or first or second shell portions provides a modified release profile of the active ingredient upon contacting of the dosage form with a liquid medium.

## Claims

### Claim 1

A dosage form comprising:
(a) at least one active ingredient;
(a) a core; and
(b) a shell which resides upon at least a portion of the core, wherein the shell is substantially free of pores having a diameter of 0.5 to 5.0 microns; the shell comprises a first shell portion and a second shell portion which are compositionally different; and the dosage form provides a modified release profile of the active ingredient upon contacting of the dosage form with a liquid medium.

### Claim 2 (depends on 1)

The dosage form of claim 1, in which at least one of the first or second shell portions comprises means for modifying the release profile of an active ingredient contained either in (i) the core or (ii) the shell portion comprising the means for modifying the release profile upon contacting of the dosage form with a liquid medium.

### Claim 3 (depends on 1)

The dosage form of claim 1 in which at least one of the first or second shell portions comprises an active ingredient.

### Claim 4 (depends on 1)

The dosage form of claim 1, in which the first and second shell portions each comprise an active ingredient.

### Claim 5 (depends on 1)

The dosage form of claim 1, in which at least one of the first or second shell portions comprises an active ingredient which is immediately released therefrom upon contacting of the dosage form with a liquid medium.

### Claim 6 (depends on 1)

The dosage form of claim 1, in which at least one of the first or second shell portions provides modified release of at least one active ingredient contained therein.

### Claim 7 (depends on 1)

The dosage form of claim 1, in which at least one of the first or second shell portions comprises at least one active ingredient, and the release of the active ingredient contained in the shell portion is sustained, prolonged, extended, or retarded upon contacting of the dosage form with a liquid medium.

### Claim 8 (depends on 4)

The dosage form of claim 4, in which the first and second shell portions each provide different release profiles for the active ingredients contained therein upon contacting of the dosage form with a liquid medium.

### Claim 9 (depends on 1)

The dosage form of claim 1, in which at least one of the first or second shell portions provides modified release of at least one active ingredient contained in the underlying core or portion thereof.

### Claim 10 (depends on 1)

The dosage form of claim 1, in which the core comprises particles comprising the active material.

### Claim 11 (depends on 6)

The dosage form of claim 6, in which the particles comprise a coating capable of providing a modified release profile of the active ingredient in the particles upon contacting of the core with a liquid medium.

### Claim 12 (depends on 1)

The dosage form of claim 1, in which the core comprises a first core portion and a second core portion, at least one core portion comprises at least one active ingredient, and at least one active ingredient contained in the first or second core portion exhibits a modified release profile upon contacting of the dosage form with a liquid medium.

### Claim 13 (depends on 1)

The dosage form of claim 1, in which the core comprises a first core portion and a second core portion, at least one core portion comprises at least one active ingredient, and the first or second core portion comprises a material which provides a modification to the release of an active ingredient contained therein upon contacting of the dosage form with a liquid medium.

### Claim 14 (depends on 1)

The dosage form of claim 1, in which the core comprises a first core portion and a second core portion, at least one core portion comprises at least one active ingredient, and the first or second shell portion comprises a material which provides a modification to the release of an active ingredient contained in the underlying core portion upon contacting of the dosage form with a liquid medium.

### Claim 15 (depends on 1)

The dosage form of claim 1, in which the core comprises a first core portion and a second core portion, at least one core portion comprises at least one active ingredient, and the release of the active ingredient contained in the core portion is delayed upon contacting of the dosage form with a liquid medium.

### Claim 16 (depends on 1)

The dosage form of claim 1, in which the core comprises a first core portion and a second core portion, and at least one core portion comprises at least one active ingredient, and the release of the active ingredient contained in the core portion is sustained, prolonged, extended, or retarded upon contacting of the dosage form with a liquid medium.

### Claim 17 (depends on 1)

The dosage form of claim 1, in which at least one of the first or second core portions comprises an active ingredient which is immediately released therefrom upon breach of the surrounding shell portion and contacting of the core portion with a liquid medium.

### Claim 18 (depends on 1)

The dosage form of claim 1, in which the core comprises a first core portion and a second core portion, each core portion comprises an active ingredient, and each of the active ingredients exhibits a modifed release profile upon contacting of the dosage form with a liquid medium.

### Claim 19 (depends on 18)

The dosage form of claim 18, in which the release profiles of the active ingredients in the first and second core portions are substantially similar.

### Claim 20 (depends on 18)

The dosage form of claim 18, in which the release profiles of the first and second core portions are substantially different.

### Claim 21 (depends on 1)

The dosage form of claim 1, in which the core comprises a first core portion and a second core portion, only one of the first or second core portions comprises an active ingredient, and the active ingredient exhibits a modifed release profile upon contacting of the dosage form with a liquid medium.

### Claim 22 (depends on 1)

The dosage form of claim 1, in which the core is a bi-layer tablet.

### Claim 23 (depends on 1)

The dosage form of claim 1, in which at least one of the first or second core portions comprises particles comprising at least one active ingredient.

### Claim 24 (depends on 23)

The dosage form of claim 23, in which the particles comprise a coating capable of providing a modifed release profile of the active ingredient in the particles upon contacting of the core with a liquid medium.

### Claim 25 (depends on 1)

The dosage form of claim 1, in which the core is substantially free of pores having a diameter of 0.5-5.0 microns.

### Claim 26

A dosage form comprising:
(a) at least one active ingredient;
(b) a core comprising first and second core portions; and
(c) a shell portion which surrounds at least one of the first or second core portions.

### Claim 27

A dosage form comprising:
(a) at least one active ingredient;
(b) a core comprising first and second core portions; and
(c) a shell portion which surrounds only the first core portion, wherein the second core portion is not enclosed by a shell portion, and the second core portion is exposed immediately to the liquid medium upon contact of the dosage form with a liquid medium.

### Claim 28

A dosage form comprising:
(a) at least one active ingredient;
(b) a core comprising first and second core portions; and
(c) a shell which resides upon at least a portion of the core, wherein the shell comprises first and second shell portions such that the first shell portion resides upon at least a portion of the first core portion and the second shell portion resides upon at least a portion of the second core portion, and at least one of the first or second core portions or first or second shell portions provides a modified release profile of an active ingredient upon contacting of the dosage form with a liquid medium.

### Claim 29 (depends on 28)

The dosage form of claim 28, in which the first core portion comprises a first active ingredient, and the second core portion does not comprise an active ingredient.

### Claim 30 (depends on 28)

The dosage form of claim 28, in which the first core portion comprises a first active ingredient, and the second core portion comprises a second active ingredient.

### Claim 31 (depends on 30)

The dosage form of claim 30, in which the first shell portion provides for modified release of the first active ingredient, and the second shell portion provides for modified release of the second active ingredient.

### Claim 32 (depends on 30)

The dosage form of claim 30, in which the first shell portion provides for immediate release of the first active ingredient, and the second shell portion provides for modified release of the second active ingredient.

### Claim 33 (depends on 28)

The dosage form of claim 28, in which the first core portion comprises a first active ingredient, the second core portion comprises a second active ingredient, the first shell portion comprises a third active ingredient, and the second shell portion comprises a fourth active ingredient.

### Claim 34 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein the dosage form comprises means for providing an erosion controlled release profile of at least one active ingredient.

### Claim 35 (depends on 34)

The dosage form of claim 34, wherein the dosage form comprises means for providing an erosion controlled release profile of an active ingredient contained in the core.

### Claim 36 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein the dosage form comprises means for providing a diffusion controlled release profile of at least one active ingredient.

### Claim 37 (depends on 36)

The dosage form of claim 36, wherein the dosage form comprises means for providing a diffusion controlled release profile of an active ingredient contained in the core.

### Claim 38 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein the dosage form comprises means for providing an immediate release profile for an active ingredient contained in the shell.

### Claim 39 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein the dosage form comprises means for providing a delayed release profile for an active ingredient contained in the core.

### Claim 40 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein the dosage form comprises means for providing an immediate release profile of an active ingredient contained in the core upon a breach of the shell by the liquid medium.

### Claim 41 (depends on 28)

The dosage form of claim 28, in which at least one of the first or second core portions is substantially free of pores having a diameter of 0.5-5.0 microns.

### Claim 42 (depends on 28)

The dosage form of claim 28, in which at least one of the first or second shell portions is substantially free of pores having a diameter of 0.5-5.0 microns.

### Claim 43 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein the dosage form comprises means for providing a pulsatile release profile of at least one active ingredient.

### Claim 44 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein one or more shell portions prevent release therethrough of an active ingredient contained in the underlying core or core portion.

### Claim 45 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein at least one of the first or second shell portions comprises a thermal-reversible carrier selected from the group consisting of polyethylene glycol, polyethylene oxide and combinations thereof.

### Claim 46 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein at least one of the first or second shell portions comprises a release modifying excipent selected from the group consisting of shellac, hydroxypropylmethylcellulose, polyethylene oxide, ammonio methacrylate copolymer type B, and combinations thereof.

### Claim 47 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein at least one of the first or second shell portions comprises a film-former selected from the group consisting of cellulose acetate, ammonio methacrylate copolymer type B, shellac, hydroxypropylmethylcellulose, and combinations thereof.

### Claim 48 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein at least one of the first or second shell portions comprises a swellable erodible hydrophilic material selected from the group consisting of selected from cross-linked polyvinyl pyrrolidone, cross-linked agar, cross-linked carboxymethylcellose sodium, and combinations thereof.

### Claim 49 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein at least one of the first or second shell portions further comprises a plasticizer.

### Claim 50 (depends on 1, 28)

The dosage form of claim 1 or claim 28, wherein at least one of the first or second shell portions comprises a pore former.

### Claim 51 (depends on 1, 28)

The dosage form of claim 1 or claim 28, further comprising an outer coating which covers at least a portion of the shell.
